Ocugen, Inc. (NASDAQ:OCGN) Q4 2022 Earnings Conference Call February 27, 2023 8:30 AM ET

Company Participants

Tiffany Hamilton - Head of Corporate Communications

Shankar Musunuri - Chairman, Chief Executive Officer & Co-Founder

Jessica Crespo - Chief Accounting Officer & Senior Vice President, Finance

Conference Call Participants

Uy Ear - Mizuho Securities

Jennifer Kim - Cantor Fitzgerald

Jonathan Aschoff - ROTH Capital Partners

Robert LeBoyer - Noble Capital Markets

Sean Lee - H.C. Wainwright

Daniil Gataulin - Chardan

Operator

Good morning and welcome to Ocugen’s Fourth Quarter and Full Year 2022 Financial Results and Business Update Call. Please note that this call is being recorded at this time. Following the speaker's commentary there will be a Question-and-Answer Session.

I will now turn the call over to Tiffany Hamilton, Ocugen’s Head of Corporate Communications. You may begin.

Tiffany Hamilton

Thank you. Joining me today are Ocugen's Chairman, CEO and Co-Founder, Dr. Shankar Musunuri who will provide a business update and our Chief Accounting Officer and Senior Vice President of Finance, Jessica Crespo, who will provide more detail on our financial results. Earlier this morning, we issued a press release detailing business and operational highlights for the fourth quarter and full year of 2022. We encourage listeners to review the press release, which is available on our website at oxygen.com. This call is being recorded, and a replay of the accompanying slide presentation will be available on the Investors section of the Ocugen website for approximately 45 days.

This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties. We may, in some cases, use terms such as predict, believe, potential, propose continue, estimate, anticipate, expect, plan, intend, may, could, might, will, should or other words that convey uncertainties of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from our current expectations. Investors should familiarize themselves with the company's filings for complete details. Except as required by law, we assume no obligation to update forward-looking statements contained in this presentation. whether as a result of new information, future events or otherwise after the date of this presentation. Finally, Ocugen's 10-K covering 2022 will be filed soon after today's call.

I will now turn the call to Dr. Musunuri.